Pharmaceuticals

Global Arcalyst (rilonacept) Market 2026–2030: Forecast Insights for Business Planning

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the arcalyst (rilonacept) market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Arcalyst (rilonacept) Market from 2026 to 2030?

The market size for arcalyst (rilonacept) has experienced significant expansion in recent years. It is projected to increase from $0.24 million in 2025 to $0.26 million in 2026, reflecting a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to various factors, including the identification of il 1 driven diseases, the scarcity of alternative treatments for rare inflammatory conditions, the strong clinical outcomes demonstrated by rilonacept, the attainment of regulatory approvals for orphan indications, and the growing adoption of biologic therapies by specialists.

The market for arcalyst (rilonacept) is projected to experience robust expansion over the coming years, with its value anticipated to reach $0.33 million by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This projected increase is driven by factors such as an uptick in autoinflammatory syndrome diagnoses, the drug’s expansion into additional indications, advancements in genetic screening, enhanced accessibility to biologic therapies, and a surge in investment for rare disease treatments. Key trends during this period are expected to involve the increased embrace of IL-1 blocking therapies, greater application in uncommon autoinflammatory disorders, the development of treatments for extended inflammation control, a sharper focus on targeted cytokine inhibition, and better management strategies for chronic inflammatory ailments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19877&type=smp

What Drivers Are Affecting Demand In The Arcalyst (rilonacept) Market?

The arcalyst (rilonacept) market is anticipated to expand, driven by the increasing need for personalized medicines. Personalized medicine represents a healthcare strategy that customizes treatments and medical choices according to individual patient traits, including genetics, environment, and lifestyle. This approach is seeing a surge in demand because of its capacity to enhance treatment efficacy, minimize side effects, and account for patient-specific differences in disease progression and drug reactions. Greater adoption of personalized medicine leads to heightened awareness and more sophisticated diagnostic tools for identifying rare and genetically determined conditions. This, in turn, results in more individuals being diagnosed with conditions treatable by Arcalyst, consequently boosting the drug’s demand. For example, a report from the US-based non-profit Personalized Medicine Coalition (PMC) in February 2024 indicated that the FDA approved 16 new personalized treatments for rare disease patients in 2023, significantly more than the six approvals in 2022. Furthermore, PMC stated in February 2023 that the FDA had approved 12 new personalized medicines in 2022, marking the eighth consecutive year in which personalized medicines constituted at least a quarter of all new drug approvals. Thus, the escalating demand for personalized medicines is a key factor propelling the expansion of the arcalyst (rilonacept) market.

Which Segment Groups Are Influencing The Arcalyst (rilonacept) Market?

The arcalyst (rilonacept) market covered in this report is segmented –

1) By Type: Lyophilized, Liquid

2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency Of Interleukin-1 Receptor Antagonist (DIRA), Other Indications

3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Adult Patients, Pediatric Patients

How Are Emerging Trends Affecting The Progression Of The Arcalyst (rilonacept) Market?

Leading companies within the Arcalyst (rilonacept) market are strategically concentrating on expanding its approved uses, such as applying interleukin 1 trap therapy for recurrent pericarditis, to achieve a competitive advantage. Interleukin-1 trap therapy is a medical approach that targets and blocks surplus IL-1 proteins to alleviate detrimental inflammation throughout the body. As an illustration, in May 2024, Kiniksa Pharmaceuticals, a US-based biopharmaceutical entity, obtained FDA approval for Arcalyst to treat recurrent pericarditis. This approval highlights features like weekly subcutaneous dosing, a dual IL 1a/IL 1ß blockade, and a favorable safety record during extended use. This expansion effectively broadens Arcalyst’s accessible patient demographic beyond its initial authorization for Cryopyrin-Associated Periodic Syndromes (CAPS). Nonetheless, increased adoption could subject the drug to greater market competition, necessitate ongoing long-term safety surveillance, and attract closer examination from payors.

Who Are The Primary Competitors In The Global Arcalyst (rilonacept) Market?

Major companies operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/arcalyst-rilonacept-global-market-report-

Which Global Regions Are Shaping The Competitive Landscape Of The Arcalyst (rilonacept) Market?

North America was the largest region in the arcalyst (rilonacept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arcalyst (rilonacept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Arcalyst (rilonacept) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19877&type=smp

Browse Through More Reports Similar to the Global Arcalyst (rilonacept) Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Petrochemicals Market 2026

https://www.thebusinessresearchcompany.com/report/petrochemicals-market

Synthetic Emerald Market Report 2026

https://www.thebusinessresearchcompany.com/report/synthetic-emerald-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795